Tranexamic Acid in Treatment of Facial Erythema

Topical 10% Tranexamic Acid in Treatment of Facial Erythema and Telangiectasia With or Without Microneedling Comparative Study

Our aim is to evaluate the efficacy of 10% topical tranexamic acid with microneedling in treatment of facial erythema

Study Overview

• Status: Completed
• Conditions: Patient With Facial Erythema
• Intervention / Treatment: Drug: Tranexamic Acid 500 MG

Detailed Description

Facial erythema is redness of the skin or mucous membranes, occurs because of cutaneous blood vessel dilatation and increased blood flow to the skin.it most noticeable in fair-skinned individuals, it may be transient erythema (flushing), persistent erythema, or perilesional erythema around papules and pustules .

Flushing is a transient erythema, usually a physiological phenomenon due to strong emotion, exercise, heat exposure, hyperthermia, spicy food and alcohol intake. But it may be pathological due to pheochromocytoma, carcinoid syndrome .

Persistent erythema is facial erythema that lasts for at least 3 months. It may be due to primary skin diseases such as rosacea, demodicosis, contact dermatitis, polymorphous light eruption, acne, drug-induced (cortisone, brimonidine), lupus erythematosus or due to systemic diseases as mastocytosis, dermatomyositis and hyperthyroidism Rosacea is a chronic inflammatory skin disease characterized by erythema, papules, pustules and telangiectasia affecting the central of the face, women are more often affected than men , there are several theories regarding the cause of rosacea, including genetic, environmental, vascular, and inflammatory factors, rosacea is classified into four main subtypes erythematotelangiectatic, papulopustular, phymatous, and ocular type

Cutaneous lupus erythematosus (LE) is a common autoimmune disease which is limited to the skin, manifested with malar erythema (butterfly eruption),discoid lesions, photosensitivity . It is caused by a complex interplay between genetics, hormones and environmental factors, potential environmental triggers are ultraviolet (UV) radiation and smoking. , histopathologic findings, immunofluorescence, and antinuclear antibodies will aid in making the diagnosis Contact dermatitis of the face can present as a result of a topical causative agent, and it may represent an irritant contact dermatitis, allergic contact dermatitis. A detailed patient history reveals the application of a topical formulation or the contact with a possible precipitating factor will guide the correct diagnosis .

Acne is a multifactorial disorder of the pilosebaceous unit, characterized by non-inflammatory open or closed comedones and inflammatory papules, pustules, and nodules. may present with facial redness typically affects the areas of skin with the highest density of sebaceous follicles including the face, upper chest and back, A cardinal differential diagnosis point is the presence of comedones in acne Drug induced facial erythema due to long term use of a topical corticosteroid or after its abrupt discontinuation after long-term application. It presents with erythema, telangiectasia and papules on the areas of corticosteroid application, diagnosis is based on the monomorphic nature of lesions and the reported history of chronic application of a corticosteroid.

Polymorphous Light Eruption (PLE) is a common photodermatosis characterized by erythematous papules, papulovesicular, and plaques on sun-exposed areas like the face, neck, the eruption appear immediately or several hours after sun exposure and the typical occurrence in spring and early summer .

As not every patient with a facial erythema is the same so, the approach to the patient with a 'red face' includes detailed medical history , whole-body examination and additional laboratory tests are required to confirm the suspected diagnosis .

Traditional options for treatment of facial erythema include the topical brimonidine tartrate , oxymetazoline , have high recurrence rate and Pulsed Dye Laser or Intense pulsed light (IPL) they are rather expensive , although these methods usually show satisfactory results, they are unable to meet the modern patient's need to improve his/her appearance. Therefore, novel and more effective treatment sought by dermatologists.

Tranexamic acid, is an antifibrinolytic drug (synthetic lysine-like molecule) that Works by preventing blood clots from breaking down too quickly , it is used to prevent excessive blood loss from major trauma, postpartum bleeding, heavy menstruation and nose bleeds Tranexamic acid acting by competitively inhibits the activation of plasminogen to plasmin so, suppress plasmin-induced angiogenesis. It also suppressing pro-inflammatory cytokines (interleukin 6 and tumor necrosis factor alpha). Moreover, it can restore the compromised epidermal permeability barrier function and thus decreasing erythema . So, we aimed to evaluate the efficacy of 10% topical tranexamic acid in treatment of facial erythema with microneedling.

• Study Type: Interventional
• Enrollment (Actual): 50
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Egypt
  • Assiut, Egypt
    • Azhar University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

Female Patients clinical diagnosis with persistent facial erythema and telangiectasia. Co-operative patient and patients willing for the procedure

Exclusion Criteria:

active infection at the local site or recurrent herpes. bleeding disorders or anticoagulant medications scar and keloid formation. unrealistic expectations. Pregnant or lactating women

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: single group	Drug: Tranexamic Acid 500 MG; Each patient received treatment on both sides of the face, one side treated by micro needling with 10% topical tranexamic acid, and othert side treated by 10% topical tranexamic acid alone every 2 weeks for 3 sessions

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
change in facial erythema	method of measurement by clinician erythema assessment score Description Score Clear skin with no signs of erythema 0 Almost clear; slight redness 1 Mild erythema, definite redness 2 Moderate erythema; marked redness 3 Severe erythema; fiery redness 4 by clinician erythema assesment score	after 6 week of end point

Collaborators and Investigators

• Sponsor: Azhar University

Publications and helpful links

Helpful Links

• Red face revisited: Flushing 2014.
• red face': not always rosacea 2016.
• The Great Mimickers of Rosacea 2014.

Study record dates

Study Major Dates

• Study Start (Actual): August 1, 2020
• Primary Completion (Actual): August 1, 2022
• Study Completion (Actual): August 30, 2022

Study Registration Dates

• First Submitted: June 1, 2023
• First Submitted That Met QC Criteria: June 1, 2023
• First Posted (Actual): June 9, 2023

Study Record Updates

• Last Update Posted (Actual): June 12, 2023
• Last Update Submitted That Met QC Criteria: June 9, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Skin Diseases; Disease Attributes; Skin Manifestations; Erythema; Facies; Molecular Mechanisms of Pharmacological Action; Fibrin Modulating Agents; Antifibrinolytic Agents; Hemostatics; Coagulants; Tranexamic Acid
• Other Study ID Numbers: MSc/AZAST/DVA021/18/215/1/2023

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No